MM could initiate exercising her options, which would encourage the directors and top holders to exercise the options. Then they could go for CR. Their confidence on the company would give a nice and sound message to everyone. They have a tendency to delay everyhting.
How confident are you about the potential of the complete results in securing partnership deal?
What would be their growth strategy after the complete results had been reported?
Do they have to do any further trials after these the complete results are out?
Do you find any due diligence MM made while selecting CROs?
Who would compensate for the delay causing the lapse of time to market?
Are there any scope for audits by regulators on what MM was tellign about the CROs and the preim results extending what were reported in 2018?
Their objective is to sell their platofrm and technology to a potential BP.
They have been taking money for years, how should they work seriously to bring value to the SHs?
Who should they be accountable to other than the SHs?
I understand MM's limitation, but holders wants more clarity of the delay and the prospects. We do not know why no COVID results yet, who the target BP is, and some commentaries of the SAB on the prelim.
If they are for CR, they need to announce accordingly, otherwise they need to update the market of the alternatives. Why are they silent?
BIT Price at posting:
4.6¢ Sentiment: Buy Disclosure: Held
